Literature DB >> 25944164

The role of osteopontin expression in melanoma progression.

Timea Kiss1,2, Szilvia Ecsedi1,2, Laura Vizkeleti1,2, Viktoria Koroknai1,2, Gabriella Emri3, Nora Kovács1, Roza Adany1,2, Margit Balazs4,5.   

Abstract

It was shown that osteopontin (OPN), a glycophosphoprotein, plays divergent roles in cancer progression. In addition to multiple intra- and extracellular functions, it facilitates migration of tumour cells, has crucial role in cell adhesion and is associated with increased metastasis formation. In previous studies, we performed global gene expression profiling on a series of primary melanoma samples and found that OPN was significantly overexpressed in ulcerated melanomas. The major purpose of this study was to define OPN expression in primary melanomas with differing biological behaviours. OPN mRNA expression was analysed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in primary melanoma tissues. Immunohistochemistry was performed using a tissue microarray. Cox regression tests were used for survival analysis. Greater than 50 % of the tissues exhibited high protein expression that was significantly associated with tumour thickness and metastasis. OPN mRNA expression was significantly increased in thicker melanomas and lesions with an ulcerated surface. Increased expression was primarily detected in advanced-stage tumours. A multivariate Cox regression analysis revealed that high OPN expression, tumour thickness and metastasis were significantly associated with reduced relapse-free survival. In summary, high OPN mRNA and protein expression were associated with a less favourable clinical outcome of primary melanoma patients. We determined that OPN is a significant predictive factor for the survival of primary melanoma patients. Based on our and others data, the high expression of OPN may have a crucial stimulatory role in tumour progression and metastasis formation, which, thus, have been proposed as potential targets for cancer diagnosis and therapy.

Entities:  

Keywords:  Melanoma progression; Osteopontin; Protein expression; Tissue microarray

Mesh:

Substances:

Year:  2015        PMID: 25944164     DOI: 10.1007/s13277-015-3495-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  46 in total

1.  Osteopontin expression in plasma of melanoma patients and in melanocytic tumours.

Authors:  T Maier; R P Laubender; R A Sturm; A Klingenstein; H C Korting; T Ruzicka; C Berking
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-08-12       Impact factor: 6.166

Review 2.  The regulation and role of osteopontin in malignant transformation and cancer.

Authors:  Mohamed K El-Tanani; Frederick Charles Campbell; Vittal Kurisetty; Dachuan Jin; Mella McCann; Philip S Rudland
Journal:  Cytokine Growth Factor Rev       Date:  2006-11-17       Impact factor: 7.638

3.  Osteopontin expression correlates with melanoma invasion.

Authors:  David Denhardt
Journal:  J Invest Dermatol       Date:  2005-05       Impact factor: 8.551

Review 4.  Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.

Authors:  Riku Das; Subha Philip; Ganapati H Mahabeleshwar; Anuradha Bulbule; Gopal C Kundu
Journal:  IUBMB Life       Date:  2005-06       Impact factor: 3.885

Review 5.  [Prognostic and predictive markers of malignant melanoma].

Authors:  Erzsébet Rásó; Tamás Barbai; Balázs Gyõrffy; József Tímár
Journal:  Magy Onkol       Date:  2013-05-20

Review 6.  Osteopontin: role in cell signaling and cancer progression.

Authors:  Hema Rangaswami; Anuradha Bulbule; Gopal C Kundu
Journal:  Trends Cell Biol       Date:  2006-01-10       Impact factor: 20.808

Review 7.  Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.

Authors:  Dong-Xing Cao; Zhi-Jie Li; Xiao-Ou Jiang; Yick Liang Lum; Ester Khin; Nikki P Lee; Guo-Hao Wu; John M Luk
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

Review 8.  Control of osteopontin signaling and function by post-translational phosphorylation and protein folding.

Authors:  Christian C Kazanecki; Dana J Uzwiak; David T Denhardt
Journal:  J Cell Biochem       Date:  2007-11-01       Impact factor: 4.429

Review 9.  Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology.

Authors:  Franziska Buback; Andreas C Renkl; Guido Schulz; Johannes M Weiss
Journal:  Exp Dermatol       Date:  2009-06-23       Impact factor: 3.960

Review 10.  Current management and novel agents for malignant melanoma.

Authors:  Byung Lee; Nikhil Mukhi; Delong Liu
Journal:  J Hematol Oncol       Date:  2012-02-14       Impact factor: 17.388

View more
  14 in total

Review 1.  Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma.

Authors:  Emanuelle M Rizk; Angelina M Seffens; Megan H Trager; Michael R Moore; Larisa J Geskin; Robyn D Gartrell-Corrado; Winston Wong; Yvonne M Saenger
Journal:  Am J Clin Dermatol       Date:  2020-02       Impact factor: 7.403

2.  Regulation of osteosarcoma cell invasion through osteopontin modification by miR-4262.

Authors:  Kun Song; Ning Liu; Yan Yang; Xue Qiu
Journal:  Tumour Biol       Date:  2015-12-03

Review 3.  The role of integrins in TGFβ activation in the tumour stroma.

Authors:  Zareen Khan; John F Marshall
Journal:  Cell Tissue Res       Date:  2016-08-12       Impact factor: 5.249

Review 4.  Human osteopontin: Potential clinical applications in cancer (Review).

Authors:  Chengcheng Hao; Yuxin Cui; Sionen Owen; Wenbin Li; Shan Cheng; Wen G Jiang
Journal:  Int J Mol Med       Date:  2017-04-21       Impact factor: 4.101

5.  Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.

Authors:  Amanda Psyrri; Konstantine T Kalogeras; Ralph M Wirtz; George Kouvatseas; Georgia Karayannopoulou; Anna Goussia; Flora Zagouri; Elke Veltrup; Eleni Timotheadou; Helen Gogas; Angelos Koutras; Georgios Lazaridis; Christos Christodoulou; George Pentheroudakis; Panagiota Economopoulou; Apostolos Laskarakis; Petroula Arapantoni-Dadioti; Anna Batistatou; Maria Sotiropoulou; Gerasimos Aravantinos; Pavlos Papakostas; Paris Kosmidis; Dimitrios Pectasides; George Fountzilas
Journal:  J Transl Med       Date:  2017-02-13       Impact factor: 5.531

6.  NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma.

Authors:  Claudio Guarneri; Valentina Bevelacqua; Jerry Polesel; Luca Falzone; Patrizia S Cannavò; Demetrios A Spandidos; Grazia Malaponte; Massimo Libra
Journal:  Oncol Rep       Date:  2017-01-10       Impact factor: 3.906

Review 7.  Significance of 5-S-Cysteinyldopa as a Marker for Melanoma.

Authors:  Kazumasa Wakamatsu; Satoshi Fukushima; Akane Minagawa; Toshikazu Omodaka; Tokimasa Hida; Naohito Hatta; Minoru Takata; Hisashi Uhara; Ryuhei Okuyama; Hironobu Ihn
Journal:  Int J Mol Sci       Date:  2020-01-09       Impact factor: 5.923

Review 8.  Osteopontin at the Crossroads of Inflammation and Tumor Progression.

Authors:  Luigi Mario Castello; Davide Raineri; Livia Salmi; Nausicaa Clemente; Rosanna Vaschetto; Marco Quaglia; Massimiliano Garzaro; Sergio Gentilli; Paolo Navalesi; Vincenzo Cantaluppi; Umberto Dianzani; Anna Aspesi; Annalisa Chiocchetti
Journal:  Mediators Inflamm       Date:  2017-07-09       Impact factor: 4.711

9.  Ectopic expression of the osteogenic master gene RUNX2 in melanoma.

Authors:  Maria Teresa Valenti; Luca Dalle Carbonare; Monica Mottes
Journal:  World J Stem Cells       Date:  2018-07-26       Impact factor: 5.326

10.  BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway.

Authors:  Guangtong Deng; Furong Zeng; Juan Su; Shuang Zhao; Rui Hu; Wu Zhu; Shuo Hu; Xiang Chen; Mingzhu Yin
Journal:  Theranostics       Date:  2020-09-15       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.